stockrowWarby Parker Inc.
WRBY Healthcare Medical Instruments & Supplies
Warby Parker Inc.’s revenue for fiscal 2025 (year ended December 2025) was $871.9 million, up 13.0% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −20.0%
- Free cash flow
- −30.3%
Quarter to September 2026, against a year earlier
Follow WRBY
Alert me
Warby Parker Inc. (WRBY) EPS (diluted)
Warby Parker Inc.'s EPS (diluted) for fiscal 2025 was $0.01, compared with −$0.17 in fiscal 2024. Over the twelve months to 30 September 2026 it was $0.06. Over the past ten years it has ranged from −$2.21 (fiscal 2021) to $0.01 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 4 consecutive fiscal years. Warby Parker Inc. ranks 23rd of 47 Medical Instruments & Supplies companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $0.01 | — |
| FY2024 | −$0.17 | — |
| FY2023 | −$0.54 | — |
| FY2022 | −$0.96 | — |
| FY2021 | −$2.21 | — |
| FY2020 | −$1.05 | — |
| FY2019 | −$1.10 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.04 | 0.00% |
| Jun 2026 | $0.04 | 33.33% |
| Mar 2026 | $0.03 | — |
| Dec 2025 | −$0.05 | — |
| 22 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| LMAT LeMaitre Vascular, Inc. compare | $2.75 |
| ICUI ICU Medical, Inc. compare | $2.39 |
| STVN Stevanato Group S.p.A. compare | $0.59 |
| ATRC AtriCure, Inc. compare | $0.30 |
| WRBY Warby Parker Inc. | $0.06 |
| XRAY DENTSPLY SIRONA Inc. compare | −$0.62 |
| PLSE Pulse Biosciences, Inc compare | −$1.21 |
| AZTA Azenta, Inc. compare | −$2.67 |
| KMTS Kestra Medical Technologies, Ltd. compare | −$2.67 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on WRBY
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement